In this regard, HDAC6 inhibitors were found to reduce cytokine release, decrease T cell exhaustion, and contribute to innate immune cell memory processes, potentially providing therapeutic benefits in severe COVID-19 cases. This evidence concerns the gene HDAC6 and COVID-19.